These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 30882160)

  • 1. Treatment Satisfaction with Flexible-dose Fesoterodine in Patients with Overactive Bladder who were Dissatisfied with Previous Anticholinergic Therapy: A Multicenter Single-Arm Clinical Study.
    Choi JB; Cho KJ; Park WH; Lee DH; Kim YH; Cho IR; Yoon H; Kim YS; Kim JC
    Urol J; 2020 Jan; 17(1):97-101. PubMed ID: 30882160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of flexible-dose fesoterodine on overactive bladder symptoms and treatment satisfaction: an open-label study.
    Wyndaele JJ; Goldfischer ER; Morrow JD; Gong J; Tseng LJ; Guan Z; Choo MS
    Int J Clin Pract; 2009 Apr; 63(4):560-7. PubMed ID: 19348029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Superiority of fesoterodine 8 mg vs 4 mg in reducing urgency urinary incontinence episodes in patients with overactive bladder: results of the randomised, double-blind, placebo-controlled EIGHT trial.
    Chapple C; Schneider T; Haab F; Sun F; Whelan L; Scholfield D; Dragon E; Mangan E
    BJU Int; 2014 Sep; 114(3):418-26. PubMed ID: 24552358
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of fesoterodine and tolterodine extended release for the treatment of overactive bladder: a head-to-head placebo-controlled trial.
    Herschorn S; Swift S; Guan Z; Carlsson M; Morrow JD; Brodsky M; Gong J
    BJU Int; 2010 Jan; 105(1):58-66. PubMed ID: 20132103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms.
    Kaplan SA; Roehrborn CG; Gong J; Sun F; Guan Z
    BJU Int; 2012 Jun; 109(12):1831-40. PubMed ID: 21966995
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fesoterodine for the Treatment of Nocturnal Urgency in Patients with Overactive Bladder Syndrome: An Analysis of Responders and Nonresponders.
    Khusid JA; Weiss JP; Carlsson MO; Mangan EK
    J Urol; 2017 Nov; 198(5):1119-1123. PubMed ID: 28479240
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of fesoterodine in vulnerable elderly subjects with urgency incontinence: a double-blind, placebo controlled trial.
    Dubeau CE; Kraus SR; Griebling TL; Newman DK; Wyman JF; Johnson TM; Ouslander JG; Sun F; Gong J; Bavendam T
    J Urol; 2014 Feb; 191(2):395-404. PubMed ID: 23973522
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of flexible dose fesoterodine in men and women with overactive bladder symptoms including nocturnal urinary urgency.
    Weiss JP; Jumadilova Z; Johnson TM; Fitzgerald MP; Carlsson M; Martire DL; Malhotra A
    J Urol; 2013 Apr; 189(4):1396-401. PubMed ID: 23159276
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of voluntary dose escalation in a placebo-controlled, flexible-dose trial of fesoterodine in subjects with overactive bladder.
    Staskin D; Khullar V; Michel MC; Morrow JD; Sun F; Guan Z; Dmochowski R
    Neurourol Urodyn; 2011 Nov; 30(8):1480-5. PubMed ID: 21560158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and tolerability of fesoterodine versus tolterodine in older and younger subjects with overactive bladder: a post hoc, pooled analysis from two placebo-controlled trials.
    DuBeau CE; Morrow JD; Kraus SR; Creanga D; Bavendam T
    Neurourol Urodyn; 2012 Nov; 31(8):1258-65. PubMed ID: 22907761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of fesoterodine compared with extended-release tolterodine in men and women with overactive bladder.
    Ginsberg D; Schneider T; Kelleher C; Van Kerrebroeck P; Swift S; Creanga D; Martire DL
    BJU Int; 2013 Aug; 112(3):373-85. PubMed ID: 23826844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flexible-dose fesoterodine in elderly adults with overactive bladder: results of the randomized, double-blind, placebo-controlled study of fesoterodine in an aging population trial.
    Wagg A; Khullar V; Marschall-Kehrel D; Michel MC; Oelke M; Darekar A; Bitoun CE; Weinstein D; Osterloh I
    J Am Geriatr Soc; 2013 Feb; 61(2):185-93. PubMed ID: 23350833
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do patient characteristics predict which patients with overactive bladder benefit from a higher fesoterodine dose?
    Goldman HB; Oelke M; Kaplan SA; Kitta T; Russell D; Carlsson M; Arumi D; Mangan E; Ntanios F
    Int Urogynecol J; 2019 Feb; 30(2):239-244. PubMed ID: 29600400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of fesoterodine on nocturia and quality of sleep in Asian patients with overactive bladder.
    Yokoyama O; Hiro S; Hotta S; Mogami S; Yamagami H
    Urology; 2014 Apr; 83(4):750-5. PubMed ID: 24518285
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fesoterodine in patients with overactive bladder syndrome: can the severity of baseline urgency urinary incontinence predict dosing requirement?
    Cardozo L; Khullar V; Wang JT; Guan Z; Sand PK
    BJU Int; 2010 Sep; 106(6):816-21. PubMed ID: 20151972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of fesoterodine and tolterodine in patients with overactive bladder.
    Chapple CR; Van Kerrebroeck PE; Jünemann KP; Wang JT; Brodsky M
    BJU Int; 2008 Nov; 102(9):1128-32. PubMed ID: 18647298
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of drug cessation after flexible-dose fesoterodine in patients with overactive bladder.
    Khullar V; Cardozo L; Kelleher CJ; Hall T; Ryan J; Ebel Bitoun C; Darekar A; Arumi D; Wagg A
    BJU Int; 2013 Oct; 112(6):820-9. PubMed ID: 23465055
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of flexible-dose fesoterodine in British subjects with overactive bladder: insights into factors associated with dose escalation.
    Cardozo L; Hall T; Ryan J; Ebel Bitoun C; Kausar I; Darekar A; Wagg A
    Int Urogynecol J; 2012 Nov; 23(11):1581-90. PubMed ID: 22576329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of fesoterodine treatment for overactive bladder symptoms in elderly women with and without hypertension.
    Yokoyama O; Yamagami H; Hiro S; Hotta S; Yoshida M
    Int J Urol; 2018 Mar; 25(3):251-257. PubMed ID: 29224251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of fesoterodine over 24 hours in subjects with overactive bladder.
    Staskin D; Michel MC; Nitti V; Morrow JD; Wang J; Guan Z
    Curr Med Res Opin; 2010 Apr; 26(4):813-8. PubMed ID: 20121659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.